Save
Home
GLOBAL NEWS
REUTERS
THE NEW YORK TIMES
YAHOO
US BUSINESS
CNBC
EQUITIES
THE WALL STREET JOURNAL
US MARKET
CNBC
MARKETWATCH
NASDAQ
YAHOO
US MARKET BLOGS
CNBC
REDDIT
ZERO HEDGE
US MUTUAL FUNDS BLOGS
INVESTORS BUSINESS DAILY
REDDIT
US NEWS
CNBC
MARKETWATCH
THE NEW YORK TIMES
YAHOO
 Save
{{newCountMsg}}
Settings

US MARKET | Sat, 6 Dec 2025, 12:10PM ET (RTTNews) - Genmab A/S (GMAB) announced updated findings from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered, T-cell engaging antibody.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 12:05PM ET Key Points2025 has been a year that UnitedHealth Group shareholders probably want to forget.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:56AM ET Key PointsNano Nuclear Energy is developing micro nuclear reactors.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:50AM ET Key PointsQuantum computing is expected to speed up computations exponentially when compared to standard computers.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:48AM ET (RTTNews) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV). The data, presented at the 67th American Society of Hematology (ASH) Annual Meeting and Ex

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:45AM ET Key PointsCaesars Entertainment, which owns many of the largest casino resorts in Las Vegas, was particularly hard hit by declining tourism to Sin City.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:35AM ET Key PointsCoreWeave's AI-ready cloud platforms have benefited from unprecedented demand growth.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:20AM ET Key PointsNuclear power is regaining popularity due to its efficiency, reliability, and zero emissions.

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:13AM ET (RTTNews) - Johnson & Johnson (JNJ) announced updated results from the Phase 3 CARTITUDE-4 study, reinforcing the potential of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) to deliver durable, treatment-free remissions in patients with relapsed or refractory multiple myeloma (R

Continue reading at Nasdaq

1h

US MARKET | Sat, 6 Dec 2025, 11:05AM ET Key PointsVistra Corp. slightly underperformed the market over the past year.

Continue reading at Nasdaq

2h
more